The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin

British Journal of Clinical Pharmacology

Volumn 49, Issue 2, 2000, Pages 98-103

  Kamberi, Marika ^a   Nakashima, Hajime ^a   Ogawa, Keita ^a   Oda, Naomi ^a   Nakano, Shigeyuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Drug interaction; Sparfloxacin; Sucralfate

Indexed keywords

DRUG METABOLITE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SUCRALFATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; METABOLIC CLEARANCE RATE; SUCRALFATE; TIME FACTORS;

EID: 0033977858     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00118.x     Document Type: Article

References (28)

1. 1 Stein GE. Drug interaction with fluoroquinolones. Am J Med Supplement 1991; 6A: 81-86.
2. 2 Lewin CS, Smith JT. 4-quinolones and multivalent ions. [Letter]. J Antimicrob Chemother 1990; 26: 149.
3. 3 Polk RE, Healy DP, Sahai J, Drowal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989; 33: 1841-1844.
4. 4 Janknegt R. Drug interactions with quinolones. J Antimicrob Chemother 1990; 26(Suppl D): 7-29.
5. 5 Kanemitsu K, Hori S, Yanagawa A, Shimada J. Effect of ferrous sulfate on absorption of sparafloxacin in healthy volunteers and rats. Drugs 1995; 49(Suppl 2): 352-356.
6. 6 Zix JA, Geerdes-Fenge HF, Rau M, et al. Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate. Antimicrob Agents Chemother 1997; 41: 1668-1672.
7. 7 Shiba H, Hori S, Shimada J, et al. Interaction between oral sparfloxacin and antacid in normal volunteers Eur J Clin Microbiol Infec Dis (Special Issue): 1991; 583-585.
8. 8 Noyes M, Polk RE. Norfloxacin and absorption of magnesium-aluminum. Ann Intern Med 1988; 109: 168-169.
9. 9 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A. Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother 1990; 34: 432-435.
10. 10 Flor S, Guay DRP, Opsahl JA, Tack K, Matzke GR. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavaiability of ofloxacin. Antimicrob Agents Chemother 1990; 34: 2436-2438.
11. 11 Lomaestro BM, Bailie GR. Effect of staggered dose of calcium on the bioavaiability of ciprofloxacin. Antimicrob Agents Chemother 1991; 35: 1004-1007.
12. 12 Ling-jar L, Barry HI, Der L, Hoh J, Dix R. Effects of food and sucralfate on a single oral dose of 500 Miligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 2196-2200.
13. 13 Palka E, Cuk Z. Effect of bismuth subcitrate on ciprofloxacin pharmacokinetics in beagle dogs. [Abstract no. 151]. In Abstracts of the 17th International Congress of Chemotherapy June 23-28, Berlin, Germany, 1991.
14. 14 Montay G, Bruno R, Vergniol JC, et al. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg. J Clin Pharmacol 1994; 34: 1071-1076.
15. 15 Kamberi M, Kamberi P, Nakashima H, Uemura N, Nakamura K, Nakano S. Determination of sparfloxacin in plasma and urine by a simple and rapid liquid chromatography method. Ther Drug Monit 1999; 21: 411-415.
16. 16 Determination of AT-4140 and its metabolotes in plasma urine and bile; Document AT, 4140-D, 103 Dainippon Pharmaceutical Co.; Osaka, Japan, 1991.
17. 17 Nagashima R. Development and characteristics of sucralfate. J Clin Gastroenterol 1981; 3(Suppl 2): 103-110.
18. 18 Hollander D. Efficacy of sucralfate for duodenal ulcers: a multi-center, double-blind trial. J Clin Gastroenterol 1981; 3(Suppl2): 153-157.
19. 19 Haram EM, Weberg R, Berstad A. Urinary excretion of aluminum after ingestion of sucralfate and an aluminum-containing antiacid in man. Scand J Gastroenterol 1987; 22: 615-618.
20. 20 Pai S, Melethil S, Cuddy P, Hall T. Elevation of serum aluminum in humans on a two day sucralfate regimen. J Clin Pharmacol 1987; 27: 213-215.
21. 21 Nakano M, Yamamoto M, Arita T. Interactions of aluminum, magnesium, and calcum ions with naldixic acid. Chem Pharm Bull 1978; 26: 1505-1510.
22. 22 Robson RA. Quinolone pharmacokinetics. Int J Antimicrob Agents 1992; 2: 3-10.
23. 23 Wolfson JS, Hooper DC. Pharmacokinetic of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 1991; 10: 267-274.
24. 24 Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic /pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokin 1995; 28: 143-160.
25. 25 Parpia SH, Nix DE, Hajinanowski LG, Goldstein RH, Wilton JH, Schetang JJ. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 1989; 33: 99-102.
26. 26 Ryerson B, Toothtaker R, Chleger I, Sedman A, Colburn W. Effect of sucralfate on enoxacin pharmacokinetics. Program Abstract. 29th Intersci Conf Antimicrob Agents Chemother; Abstract 214, 1989.
27. 27 Costc T, Rautureau J, Beaugrant M, et al. Comparison of two sucralfate dosages presented in tablet form in duodenal ulcer healing. Am J Med 1987; 6: 105-117.
28. 28 Johnson R, Geary W, Jenssen B. The absolute oral bioavailability of sparfloxacin in healthy male subjects (Abstract). Presented at the 36th Interscience Conference on Antimicrob Agents and Chemother; New Orleans, 1996.